Artiva Biotherapeutics, Inc.’s Lock-Up Period To Expire Tomorrow (NASDAQ:ARTV)

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period will end on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its initial public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ARTV. HC Wainwright assumed coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $21.00.

Artiva Biotherapeutics Stock Down 18.1 %

ARTV opened at $7.66 on Tuesday. Artiva Biotherapeutics has a 52-week low of $7.60 and a 52-week high of $17.31. The stock’s 50 day simple moving average is $11.27.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, research analysts predict that Artiva Biotherapeutics will post -4.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp bought a new position in Artiva Biotherapeutics during the 3rd quarter worth $1,337,000. Geode Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the third quarter worth about $4,774,000. BNP Paribas Financial Markets bought a new position in shares of Artiva Biotherapeutics during the third quarter worth about $42,000. Barclays PLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth about $304,000. Finally, Franklin Resources Inc. bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at about $7,435,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.